Clinical Trials Logo

Clinical Trial Summary

The purpose of the study is to assess the success of a single administration of Staccato alprazolam compared with placebo both in rapidly terminating a seizure episode within 90 seconds and with no recurrence of seizure(s) up to 2 hours after investigational medicinal product (IMP) administration.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05077904
Study type Interventional
Source UCB Pharma
Contact UCB Cares
Phone 1-844-599-2273 (USA)
Email UCBCares@ucb.com
Status Recruiting
Phase Phase 3
Start date December 7, 2021
Completion date April 17, 2024